Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.410
+0.047 (3.45%)
At close: Apr 13, 2026, 4:00 PM EDT
1.402
-0.008 (-0.60%)
After-hours: Apr 13, 2026, 7:59 PM EDT
Quince Therapeutics Employees
Quince Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 4 or 12.50% compared to the previous year.
Employees
36
Change (1Y)
4
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,332,750
Market Cap
7.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | 38 | 15 | 65.22% | 37 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| BioAtla | 41 |
| Processa Pharmaceuticals | 12 |
| NuCana | 12 |
| MetaVia | 8 |
| TransCode Therapeutics | 7 |
| Creative Medical Technology Holdings | 4 |
| Acurx Pharmaceuticals | 4 |
QNCX News
- 14 days ago - Quince Therapeutics Settles Approximately $16.4 Million of Debt - Business Wire
- 2 months ago - Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Benzinga
- 2 months ago - Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
- 2 months ago - Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Business Wire
- 2 months ago - Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - Business Wire
- 4 months ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 4 months ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire